The role of metabolites in the causal effect of immune cell phenotypes on immunotherapy toxicity risk
{{output}}
Background: Immune checkpoint inhibitors (ICIs) therapy have significantly improved survival in cancer patients. However, immune-related adverse events (irAEs) have emerged as a major challenge limiting its therapeutic efficacy. ... ...
